{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glimepiride+%28oral%29&page=2", "query": { "intervention": "Glimepiride (oral)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glimepiride+%28oral%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glimepiride+%28oral%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T11:31:22.929Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00225264", "title": "Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "45 Years to 85 Years" }, "enrollment_count": 458, "start_date": "2003-10", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-02-28", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225264" }, { "nct_id": "NCT01496443", "title": "TAK-875 Glimepiride Drug-Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "TAK-875 and Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "68 Years", "sex": "ALL", "summary": "18 Years to 68 Years" }, "enrollment_count": 28, "start_date": "2012-01", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-13", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496443" }, { "nct_id": "NCT01087567", "title": "INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Intensive insulin", "type": "DRUG" }, { "name": "Routine Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2010-07", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 1, "location_summary": "Athens, Ohio", "locations": [ { "city": "Athens", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087567" }, { "nct_id": "NCT02419612", "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 444, "start_date": "2015-08-14", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419612" }, { "nct_id": "NCT03060980", "title": "Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "ITCA 650 20/60 mcg/day", "type": "DRUG" }, { "name": "Empagliflozin (oral)", "type": "DRUG" }, { "name": "Glimepiride (oral)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 245, "start_date": "2017-03-03", "completion_date": "2018-01-26", "has_results": false, "last_update_posted_date": "2019-03-07", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 96, "location_summary": "Fountain Hills, Arizona • Glendale, Arizona • Phoenix, Arizona + 81 more", "locations": [ { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03060980" }, { "nct_id": "NCT00775684", "title": "Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pre-diabetes", "Type 2 Diabetes" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 47, "start_date": "2008-10", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2022-06-07", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775684" }, { "nct_id": "NCT03332771", "title": "Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Sotagliflozin (SAR439954)", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 954, "start_date": "2017-12-01", "completion_date": "2019-09-06", "has_results": true, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 115, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332771" }, { "nct_id": "NCT00622284", "title": "Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo identical to BI 1356 5mg", "type": "DRUG" }, { "name": "Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg", "type": "DRUG" }, { "name": "BI 1356", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1560, "start_date": "2008-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 23, "location_summary": "Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622284" }, { "nct_id": "NCT00740051", "title": "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Linagliptin", "type": "DRUG" }, { "name": "Linagliptin Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 227, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740051" }, { "nct_id": "NCT01494987", "title": "Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Diet", "type": "BEHAVIORAL" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 431, "start_date": "2012-01", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-07T11:31:22.929Z", "location_count": 46, "location_summary": "Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494987" } ] }